Reckitt lowers annual revenue forecast as Q3 sales miss on Lysol constraints
Reckitt (RKT) lowered its 2026 revenue growth outlook to 3.5%-4.5% from 4%-5% after Q3 sales missed estimates, with North America down 1.3% due to Lysol production constraints. Core Reckitt Q3 revenue was £2.69B, up 3.3%. Emerging markets grew 8%, while Europe saw 0.8% growth. Adjusted operating margin targets remain unchanged.
How this was made
The 30-second read
Why it matters
The revenue guidance downgrade reflects manufacturing bottlenecks for Lysol, a core product, and may trigger a sell‑off in the stock.
Market read
Guidance cut is the primary catalyst for short‑term price movement in RKT.
What to watch
Strong growth in emerging markets and Europe could offset North America weakness.
Background
Reckitt Benckiser is a global consumer health and hygiene company listed in the US as RKT.
Ticker impact
Reckitt lowered its 2026 revenue growth outlook to 3.5%-4.5% from 4%-5% after Q3 sales missed forecasts.
likely downward pressure as the market prices in the lower revenue outlook
Investors typically react negatively to reduced guidance, especially when driven by capacity constraints.
Market effects
Consumer health sector may see broader concerns over supply constraints.
North American consumer staples could face slight weakness.
Limited to Reckitt and its peers; no major macro ripple.
Counterpoint
If capacity upgrades resolve quickly, the cut may be temporary and present a buying opportunity.
Key entities
- personKris Licht
Chief Executive Officer of Reckitt.
